SCIENTIFIC LETTER

Prognostic value of elevated biomarkers in diabetic and non-diabetic patients admitted for acute coronary syndromes

R Fazel, J Fang, E Kline-Rogers, D E Smith, K A Eagle, D Mukherjee

Heart 2005;91:388–390. doi: 10.1136/hrt.2003.032797

Diabetes is not only a predisposing factor for cardiovascular disease but once diabetic patients develop coronary artery disease (CAD) they have significantly worse outcomes compared to non-diabetic patients.^{1,2} Diabetes is an independent risk factor for a worse outcome after presentation with acute coronary syndrome (ACS).²

Prior studies have demonstrated that diabetic patients without previous myocardial infarction have as high a risk as non-diabetic patients with previous myocardial infarction.³ Based on this and other studies, diabetes is considered a CAD equivalent or, in other words, patients with diabetes should be treated as already having vascular disease. Elevated cardiac enzymes, both creatine kinase myocardial band (CK-MB) and troponin, have been demonstrated to be important prognostic determinants of patients with ACS and to identify high risk patients.⁴ The prognostic implications of elevated biomarkers in diabetic patients who are already considered to be at high risk have not been systematically studied.

METHODS

The primary objective was to analyse the prognostic implication of elevated biomarkers in patients with and without diabetes in predicting six month mortality. We studied 1951 consecutive patients who were admitted to the University of Michigan Medical Center from 27 December 1998 to 16 October 2002 with a diagnosis of ACS. The protocol was approved by the institutional review board at the University of Michigan and informed consent obtained from all patients. Diabetes was defined as a known history of type 1 or type 2 diabetes mellitus treated with diet, oral glucose lowering agents, or insulin. Patients utilising insulin for the management of their diabetes before admission were included in the insulin treated diabetic patient subset. Univariate statistics are presented as frequency and percentage for categorical variables, and mean and standard deviation for continuous variables. Probability (p) values for comparisons of the distributions of categorical variables between diabetic and non-diabetic patients were based on χ^2 tests; p values for comparisons of continuous variables between diabetic and non-diabetic groups were based on t tests. A multivariable logistic regression analysis was performed for six month mortality in ACS patients adjusted for age, sex, cardiovascular risk factors such as hypertension, hyperlipidaemia, smoking, renal failure, and prior myocardial infarction. All analyses were performed using SAS 8.2 (SAS Institute, Cary, North Carolina, USA).

RESULTS

Of the 1951 patients who were admitted for ACS, 598 (31%) had a previous diagnosis of diabetes mellitus. Age (63.7 (12.3) v 63.3 (14.1) years, p = 0.53) and sex (62.2% v 65.9% male, respectively, p = 0.11) were similar between diabetic

Figure 1 Cumulative six month mortality in diabetic and non-diabetic patients presenting with ACS stratified by positive cardiac enzymes (CK-MB or troponin). Non-DM (-) = non-diabetic patients without elevated cardiac enzymes; Non-DM (+) = non-diabetic patients with elevated cardiac enzymes; NDM (-) = diabetic patients without elevated cardiac enzymes; DM (+) = diabetic patients with elevated cardiac enzymes.

and non-diabetic patients. Forty nine per cent of the diabetic patients were identified as insulin treated (type of inpatient and outpatient therapy). Of the 598 patients with diabetes, approximately 71% had elevated biomarkers. Diabetic patients were less likely to present with ST elevation myocardial infarction and more likely to present with non-ST elevation myocardial infarction compared to non-diabetic patients.

Diabetic patients had higher frequencies of hyperlipidaemia, hypertension, obesity, heart failure, and previous myocardial infarction, and were more likely to have a prior diagnosis of renal insufficiency or end stage renal disease. They also had more evidence of non-cardiac vascular disease, including peripheral vascular disease and prior history of stroke or transient ischaemic attack. More diabetic patients had previously undergone percutaneous coronary intervention or coronary artery bypass grafting. Diabetic patients were less likely to be smokers.

The rates of individual in-hospital complications were increased in the diabetic patients versus non-diabetic patients (table 1). Diabetic patients experienced more heart failure, pulmonary oedema, and renal failure while in the hospital. In-hospital mortality was increased by 90% in patients with diabetes (7.3% v 4.0%, p = 0.0017; odds ratio (OR) 1.91, 95% confidence interval (CI) 1.27 to 2.88).

At six months, diabetic patients without elevated cardiac enzymes had a significantly higher mortality compared to non-diabetic patients (12.2% v 5.2%, p = 0.016) and mortality was not different compared to non-diabetic

Abbreviations: ACS, acute coronary syndrome; CAD, coronary artery disease; CK-MB, creatine kinase myocardial band

Figure 2 Multivariable predictors of six month mortality after ACS in patients stratified by diabetic status and elevated biomarkers. Non-diabetic patients without elevated cardiac enzymes were used as the reference group. Non-DM (+) = non-diabetic patients with elevated cardiac enzymes; DM (-) = diabetic patients without elevated cardiac enzymes; DM (+) = diabetic patients with elevated cardiac enzymes. Diabetic patients without elevated biomarkers had equivalent risk compared to non-diabetic patients who had positive biomarkers. The C index for the model was 0.76; Hosmer-Lemeshow test statistic was 0.44.

Table 1 Demographics, management, and clinical outcomes of patients presenting with ACS stratified by diabetes			
	Diabetic patient (n = 598)	Non-diabetic patient (n = 1353)	p Value
Demographics			
Mean age (years)	63.7 (12.3)	63.3 (14.1)	0.53
Male	62.2%	65.9%	0.11
Prior myocardial infarction	50.2%	37.2%	<0.01
Prior transient ischaemic attack/stroke	15.5%	10.1%	<0.01
Hypertension	81.4%	61%	<0.01
Hyperlipidaemia	68.1%	58.4%	<0.01
Renal insufficiency	16.2%	5.3%	<0.01
Hypertension	81.4%	61%	<0.01
Peripheral vascular disease	20.7%	12.6%	<0.01
Positive biomarkers	69.2%	71.1%	0.38
Ejection Fraction	46.9%	49.6%	0.03
Management			
Percutaneous coronary intervention	37.1%	42.7%	0.01
Coronary artery bypass grafting	8.4%	8.1%	0.86
Intravenous glycoprotein IIb/IIIa	21.7%	23.2%	0.48
Thrombolytics	5.1%	7.9%	0.01
In-hospital events			
Death	7.3%	4.0%	<0.01
Reinfarction	1.6%	1.1%	0.38
Stroke	0.84%	1.33%	0.34
Pulmonary oedema	10.7%	7.3%	0.01
Major bleeding	9.4%	7.8%	0.24
Events by 6 months			
Death	14.2%	8.4%	<0.01
Reinfarction	6.0%	4.9%	0.42
Stroke	1.9%	1.1%	0.20
Rehospitalisation for ACS	31.3%	25.2%	0.02

patients with elevated cardiac enzymes (12.2% v 9.7%, p = 0.19) (fig 1). After multivariate adjustment for baseline demographics and co-morbidities, diabetic patients without elevated biomarkers had equivalent risk compared to non-diabetic patients with positive biomarkers (fig 2). Diabetic patients with elevated biomarkers were at the highest risk. The multivariate model demonstrated that diabetic patients on insulin had a trend towards higher mortality compared to diabetic patients treated with diet or an oral hypoglycaemic (OR 1.78; 95% CI 0.98 to 3.26, p = 0.06).

DISCUSSION

Previous studies have shown that after an acute myocardial infarction, diabetic patients have worse in-hospital outcomes

compared to non-diabetic patients. Several prior studies have demonstrated the unequivocal prognostic implications of elevated cardiac enzymes in patients presenting with ACS.³ An important observation from our study is that the prognosis of diabetic patients presenting with ACS without elevated cardiac enzymes is comparable to non-diabetic patients with elevated cardiac enzymes. Thus diabetic patients who present with ACS but do not have elevated cardiac enzymes (CK-MB or troponin) should probably be treated as aggressively as individuals with elevated biomarkers to try to improve outcomes.

A potential limitation of this study is that determination >of the presence of diabetes mellitus was done by history alone. Thus, the non-diabetic patient group may have included some patients with undiagnosed diabetes or subclinical insulin resistance, the metabolic syndrome that puts patients at higher risk for coronary events.⁶ If so, the actual adverse event rate difference would be even greater than that found between the two groups of patients in this study.

This study demonstrates that diabetic patients with ACS, without elevated biomarkers, have a mortality risk similar to patients with elevated cardiac enzymes or biomarkers after adjustment for baseline demographics and co-morbidities. Thus diabetic patients presenting with ACS should be treated as aggressively as someone with positive biomarkers, which may in turn potentially translate into improved clinical outcome.

ACKNOWLEDGEMENTS

This study was supported in part by the Mardigian Foundation Grant.

Authors' affiliations

R Fazel, J Fang, E Kline-Rogers, D E Smith, K A Eagle, D Mukherjee, Department of Internal Medicine, University of Michigan Health Systems, Ann Arbor, Michigan, USA

Correspondence to: Dr Debabrata Mukherjee, Division of Cardiology, TC B1-228, The University of Michigan Medical Center, 1500 E Medical Center Drive, Ann Arbor, MI 48109-0311, USA; dmukherj@umich.edu

Accepted 24 May 2004

REFERENCES

1 Yudkin JS, Oswald GA. Determinants of hospital admission and case fatality in diabetic-patients with myocardial-infarction. *Diabetes Care* 1988;11:351-8.

2 Kouvaras G, Cokkinos D, Spyropoulou M. Increased mortality of diabetics after acute myocardial-infarction attributed to diffusely impaired left-ventricular performance as assessed by echocardiography. *Jpn Heart J* 1988;29:1-9.

- 3 Haffner SM, Lehto S, Ronnemaa T, *et al*. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. *N Engl J Med* 1998;**339**:229–34.
- 4 James S, Armstrong P, Califf R, *et al*. Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial. *Am J Med* 2003;**115**:178–84.
- 5 Newby LK, Goldmann BU, Ohman EM. Troponin: an important prognostic marker and risk-stratification tool in non-ST-segment elevation acute coronary syndromes. *J Am Coll Cardiol* 2003;**41**:31–6S.
- 6 Norhammar A, Tenerz A, Nilsson G, *et al*. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. *Lancet* 2002;**359**:2140–4.

IMAGES IN CARDIOLOGY

doi: 10.1136/hrt.2004.038687

Successful treatment of colon cancer related right heart thromboemboli with prolonged intravenous streptokinase during serial TOE monitoring

Right heart thromboemboli during pulmonary embolism (PE) implies a poor immediate prognosis. Management is still not well established, with treatment options including surgical embolectomy, anticoagulation, and thrombolysis. Transoesophageal echocardiography (TOE) has evolved as an important tool in the diagnosis and monitoring of patients with acute PE.

We describe the case of a 49 year old white woman with a history of colon cancer, under outpatient chemotherapy, who presented to the emergency department with recurrent episodes of rest dyspnoea, chest discomfort, and cough. High resolution spiral computed tomography (CT) showed multiple peripheral pulmonary emboli. Combined echocardiography (transthoracic and TOE) demonstrated a large 21×14 mm thrombus (panels A and B) attached to the lateral wall of the right atrium, and normal left ventricular (LV) and right ventricular (RV) function. She also had a Hickman catheter not related to the thrombotic mass. Doppler echocardiography revealed pulmonary hypertension with pulmonary artery (PA) systolic pressure estimated to be 49 mm Hg. A head CT was negative for bleeding or intracranial masses. Prolonged (96 hour) streptokinase infusion was started by peripheral venous access. Two days later a second TOE showed significant decrease of the thrombus (13×11 mm) (panel C) and a PA systolic pressure of 36 mm Hg. On her fifth hospital day at the end of thrombolytic infusion a third TOE examination demonstrated complete resolution of the thrombus (panel D) and near normalisation of PA systolic pressure (28 mm Hg). The patient had no haemorrhagic complications. She was placed on warfarin and was discharged home eight days after hospital admission.

P C Campos
A C Baruzzi
M L C Vieira
E Knobel
pcampos@pol.net

(A) Transoesophageal echocardiographic (TOE) four chamber view showing a large right atrial thrombus, pre-thrombolysis. (B) TOE bicaval view showing the thrombus, pre-thrombolysis. (C) Second TOE bicaval view showing a smaller thrombus after 48 hours of continuous streptokinase infusion. (D) Third TOE bicaval view showing complete resolution of the right atrial thrombus, at the end of a 96 hour streptokinase infusion. H, Hickman catheter not related to thrombus; LA, left atrium; LV, left ventricle; RA, right atrium; RV, right ventricle; T, thrombus.